Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Account Payables: 2020-2024

Historic Change in Account Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $923,323.

  • SAB Biotherapeutics' Change in Account Payables rose 149.54% to $335,924 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 669.77%. This contributed to the annual value of $923,323 for FY2024, which is 134.18% up from last year.
  • As of FY2024, SAB Biotherapeutics' Change in Account Payables stood at $923,323, which was up 134.18% from -$2.7 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Change in Account Payables registered a high of $5.2 million during FY2020, and its lowest value of -$2.9 million during FY2021.
  • For the 3-year period, SAB Biotherapeutics' Change in Account Payables averaged around -$852,607, with its median value being -$779,425 (2022).
  • As far as peak fluctuations go, SAB Biotherapeutics' Change in Account Payables crashed by 246.63% in 2023, and later skyrocketed by 134.18% in 2024.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Change in Account Payables stood at $5.2 million in 2020, then crashed by 156.33% to -$2.9 million in 2021, then surged by 73.45% to -$779,425 in 2022, then plummeted by 246.63% to -$2.7 million in 2023, then skyrocketed by 134.18% to $923,323 in 2024.